Multek Announces Completion of Acquisition by Suzhou Dongshan Precision Manufacturing (DSBJ)
Multek, a leading provider of Interconnect Solutions, today announced the completion of its previously announced acquisition by Suzhou Dongshan Precision Manufacturing Co. Ltd. (“DSBJ”) (SZSE: 002384), a diversified manufacturer headquartered in Suzhou, China. The transaction was announced in March 2018 by Multek’s outgoing parent company, Flex (NASDAQ: FLEX), in the form of a divestiture. The completion of this transaction follows the receipt of all necessary shareholder and regulatory approvals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180727005287/en/
With the completion of its change in ownership, Multek becomes an indirect, wholly-owned subsidiary of DSBJ. Franck Lize, Chief Executive Officer of Multek, commented, “We are pleased to complete this transaction and very excited about our future as part of the DSBJ family of companies. Multek is now better positioned than ever to continue expanding capabilities and contribute to the combined company’s success, while supporting our customers’ future needs.”
"This transaction represents a new chapter and key milestone in DSBJ's 38-year history," said Yuan Yonggang, Chairman and President of DSBJ. "By acquiring Multek, we are creating a more powerful and global enterprise in the component technology space, with more than 25,000 employees, over five million square feet of manufacturing space, and adding over 300 active customers including the most respected brands in the US, Europe and Asia. With the merger complete, we aim to rapidly grow Multek by repeating the same successful recipe DSBJ used to significantly grow the sales of MFLEX, our last major acquisition in 2016, which was a similar-sized manufacturer in the same industry. In addition, Multek’s large and diversified account base -- spanning Smartphones, Wearables, IoT, Automotive, Medical, Communications Infrastructure, Computing, Consumer Electronics, Industrials and Instrumentation – presents excellent cross-fertilization opportunities for DSBJ’s existing companies and vice-versa."
Founded in 1978, Multek currently operates a 1.6 million square feet campus in Zhuhai, China, offering one-stop engineering and manufacturing services for rigid Printed Circuit Board (PCBs), flexible printed circuits (FPC), rigid-flex, and assembly. Multek’s plants and laboratories are equipped with state-of-the-art equipment.
Multek, a wholly owned subsidiary of DSBJ (SZSE: 002384), is a leading value-add manufacturer of printed circuit board technologies offering a broad spectrum of PCB engineering and manufacturing expertise including high density interconnect, rigid, flexible, and rigid-flex printed circuit and assembly solutions. Serving customers in mobile, automotive, IoT, medical, wearable, telecommunications, computing, industrial and consumer electronics markets, Multek enables customers to take products to market quickly through early engineering, advanced technology new product introduction, and volume production. For more information, visit www.multek.com
DSBJ, founded in 1980 in Suzhou, was successfully listed on the Shenzhen Stock Exchange (stock code: 002384) in 2010. DSBJ aims to be a leading technology provider of critical components in the intelligent world of IoT with one-stop R&D, manufacturing, sales and service for FPC, PCB, Rigid-Flex, LED packaging, Display Modules, and Telecom equipment, which are widely applied in the consumer electronics, telecommunications, and automotive industries. DSBJ achieved annual revenue of USD 2.37 billion in 2017.
Peter Yu, +852 2276-1633
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 13:49 | Tiedote
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 20:41 | Tiedote
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 20:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 18:42 | Tiedote
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 17:00 | Tiedote
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07 | Tiedote
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme